India, May 23 -- Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion, recommending marketing authorisation of Wegovy 7.2 mg (once-weekly injectable semaglutide 7.2 mg) in a single-dose pen for people living with obesity.
Wegovy 7.2 mg is already available in the European Union for adults with obesity, dosed as three injections of 2.4 mg, and is based on results from the STEP UP trial program.
In the STEP UP trial, semaglutide 7.2 mg injected once weekly demonstrated 20.7%1 mean weight loss in participants with obesity, and approximately one in three people experienced 25% or greater weight loss.
Wegovy 7.2 mg in the single-dose pen is a...